孟鲁司特对AECOPD的疗效及对肺动脉高压的影响

目的探讨孟鲁司特治疗AECOPD急性加重期患者的临床疗效及其对患者肺动脉高压的影响。方法 80例COPD急性加重期住院患者被随机分为两组,治疗组在常规治疗的基础上加用孟鲁司特10 mg qn。对照组,仅采用常规治疗,包括氧疗、抗感染、平喘祛痰等治疗。治疗时间为14天,对两组患者分别于治疗前后根据呼吸困难程度进行评分,测定肺功能,并利用彩色超声多谱勒诊断仪测定肺动脉压力。结果治疗前两组各项指标均差异无显著性(P>0.05),治疗后两组呼吸困难程度、肺功能均较治疗前有明显改善,肺动脉压力较治疗前下降。且与对照组比较,治疗组呼吸困难改善程度及肺动脉压力下降更为显著。二者存在显著性差异(P<0.05)。结论孟鲁司特不仅可以改善COPD急性加重期患者的病情及肺功能,而且通过直接或间接作用降低肺动脉高压,对慢性肺源性心脏病的预防和治疗起着积极的作用。

Clinical effects of montelukast on acute exacerbation patients with chronic obstructive pulmonary disease(AECOPD) and its influence on pulmonary hypertension

Objective To assess the clinical effects of leukotriene receptor antagonist(LTA)-montelukast on acute exacerbation of chronic obstructive pulmonary disease(AECOPD) and its influence on pulmonary hypertension.Methods 80 patients with AECOPD were randomly divided into group A and group B.40 patients in group A were treated with the routine therapy for ten days.40 patients in group B were treated with the intervention of montelukast based on the routine therapy in the same time.The score of health-related quality of life,Pulmonary function,pulmonary hypertension were measured before and after treatment.Results Before the treatment,there were no significant diference between group A and group B(P>0.05).After treatment for 10 days,The score of health-related quality of life and Pulmonary function were significantly improved,and the pulmonary hypertension were obviously decreased in both group A and group B,but all the indexes in group A were better than those in group B(P<0.05).No obvious adverse efects were found in the period of treatment.Conclusion Montelukast Can relieve the acute exacerbation with COPD and improve the Pulmonary function of patients,and it can decline pulmonary artery pressure(PAP) through its direct and indirect effects.It plays an important role in the prevention and treatment of chronic cor pulmonale.